학술논문
Factors Associated With Declining to Participate in a Pediatric Oncology Next-Generation Sequencing Study.
Document Type
Article
Author
Howard Sharp, Katianne M.; Jurbergs, Niki; Ouma, Annastasia; Harrison, Lynn; Gerhardt, Elsie; Taylor, Leslie; Hamilton, Kayla; McGee, Rose B.; Nuccio, Regina; Quinn, Emily; Hines-Dowell, Stacy (NURSE); Kesserwan, Chimene; Sunkara, Anusha; Gattuso, Jami S. (NURSE); Pritchard, Michelle; Mandrell, Belinda; Relling, Mary V.; Haidar, Cyrine E.; Kang, Guolian; Johnson, Liza M.
Source
Subject
*CHILDHOOD cancer
*NUCLEOTIDE sequencing
*BLACK children
*DEMOGRAPHIC characteristics
*STUDENT attrition
*PEDIATRIC oncology
*
*
*
*
*
Language
ISSN
2473-4284
Abstract
PURPOSE: For the advances of pediatric oncology next-generation sequencing (NGS) research to equitably benefit all children, a diverse and representative sample of participants is needed. However, little is known about demographic and clinical characteristics that differentiate families who decline enrollment in pediatric oncology NGS research. METHODS: Demographic and clinical data were retrospectively extracted for 363 pediatric patients (0-21 years) with cancer approached for enrollment in Genomes for Kids (G4K), a study examining the feasibility of comprehensive clinical genomic analysis of tumors and paired normal samples. Demographic and clinical factors that significantly differentiated which families declined were subsequently compared, for 348 families, with enrollment in Clinical Implementation of Pharmacogenetics (PG4KDS), a pharmacogenomics study with more explicit therapeutic benefit examining genes affecting drug responses and metabolism. RESULTS: Fifty-three families (14.6%) declined enrollment in G4K. Race/ethnicity was the only variable that significantly differentiated study refusal according to multivariable logistic regression, with families of black children more likely to decline enrollment compared with families of non-Hispanic or Hispanic white children. Reasons for declining G4K were generally consistent with other pediatric genomics research: feeling overwhelmed and insurance discrimination fears were most frequently cited. Families of black children were also more likely to decline enrollment in PG4KDS. Thirteen (3.7%) of the 348 families approached for both studies declined PG4KDS. CONCLUSION: Race/ethnicity differentiated study declination across two different pediatric oncology genomics studies, suggesting enrollment disparities in the context of pediatric oncology genomics research. Genomics research participant samples that do not fully represent racial and ethnic minorities risk further exacerbating health disparities. Additional work is needed to understand the nuances of parental decision making in genomic research and facilitate enrollment of diverse patient populations. [ABSTRACT FROM AUTHOR]